Immune checkpoint inhibitors (ICIs) enable the reversion of T cell suppression and enhance anti-tumor immune responses by blocking programmed cell death 1 (PD-1, PDCD1)/programmed death-ligand 1 (PD-L1, CD274) signaling (6). Here, CD274 is linked to neoplasm.